English

Interim report quarter 2 -  Continued Efemia market expansion with Germany in sight

Report this content

SECOND QUARTER (April - June 2019)

  • The company’s sales amounted to 101 (0) KSEK.
  • Work capitalised by the company for its own use amounted to 0 (187) KSEK.
  • Operating costs amounted to 3,243 (2,043) KSEK.
  • Result after tax amounted to -3,143 (-1,857) KSEK.
  • Result per share amounted to -0.30 (-0.19) SEK.

CEO Karin Bryder summarizes the quarter 

During the second quarter of 2019, we continued to focus on establishing and marketing Invent Medic’s first product Efemia Bladder Support in Sweden, the Nordic region and Europe. The marketing activities are targeting health care entities, including relevant occupational categories, as well as consumers. Our sales revenues are still modest, but the trend is promising and the two largest pharmacy chains in Sweden are including the product in their campaigns. A positive evaluation of Efemia in Germany, with 10 million potential users, was presented during the quarter. The results contributed to us being able to sign a distribution agreement with the retail focused German company Arteriomed after the end of the period. We were also able to present positive results from a follow-up study focused on self-reported quality of life during the period.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.

Subscribe

Documents & Links